Millennium Management LLC Has $3.16 Million Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Millennium Management LLC decreased its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 64.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 123,012 shares of the company's stock after selling 219,069 shares during the period. Millennium Management LLC owned approximately 0.14% of IDEAYA Biosciences worth $3,161,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of IDYA. Rhumbline Advisers raised its position in shares of IDEAYA Biosciences by 0.5% during the 4th quarter. Rhumbline Advisers now owns 113,561 shares of the company's stock worth $2,919,000 after buying an additional 585 shares in the last quarter. Daiwa Securities Group Inc. raised its position in shares of IDEAYA Biosciences by 44.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock worth $72,000 after buying an additional 853 shares in the last quarter. Mariner LLC raised its position in shares of IDEAYA Biosciences by 9.8% during the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after buying an additional 869 shares in the last quarter. Assetmark Inc. raised its position in shares of IDEAYA Biosciences by 2.5% during the 4th quarter. Assetmark Inc. now owns 45,269 shares of the company's stock worth $1,163,000 after buying an additional 1,084 shares in the last quarter. Finally, R Squared Ltd bought a new stake in shares of IDEAYA Biosciences during the 4th quarter worth about $35,000. Institutional investors own 98.29% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on IDYA. JPMorgan Chase & Co. increased their price target on IDEAYA Biosciences from $63.00 to $66.00 and gave the company an "overweight" rating in a research note on Thursday, May 22nd. Stephens restated an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday, February 14th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, IDEAYA Biosciences has a consensus rating of "Moderate Buy" and an average target price of $54.27.

IDEAYA Biosciences Stock Down 2.5%

Shares of IDYA traded down $0.54 during mid-day trading on Wednesday, hitting $21.10. 1,017,061 shares of the company's stock were exchanged, compared to its average volume of 1,018,662. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -6.39 and a beta of 0.26. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $44.42. The firm has a fifty day moving average of $18.02 and a two-hundred day moving average of $21.37.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the business posted ($0.53) EPS. On average, equities analysts predict that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.